UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2009

RAPTOR PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware	000-50720	98-0379351
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9 Commercial Blvd., Suite 200, Novato, California 94949
(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code: (415) 382-8111

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

On July 27, 2009 Raptor Pharmaceuticals Corp.’s (the “Company”) wholly-owned subsidiary, Raptor Therapeutics Inc. (“Raptor Therapeutics”), entered into a contract (the “Contract”) with Mylan Pharmaceutical Inc. (“Mylan”) effective as of July 20, 2009, pursuant to which Mylan will provide the Active Pharmaceutical Ingredient (“API”) Cysteamine Bitartrate for use in certain of the Company’s investigational drug product candidates. The initial term of the Contract is two years and will continue in effect thereafter until terminated by either party thereto.

Apart from the Contract, Mylan has no material relationship with the Company. The foregoing description of the Contract does not purport to be complete and is qualified in its entirety by reference to the Contract.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			RAPTOR PHARMACEUTICALS CORP.
			By: /s/ Kim R. Tsuchimoto
			Kim R. Tsuchimoto Chief Financial Officer, Treasurer and Secretary Date: July 31, 2009

RAPTOR PHARMACEUTICALS CORP. 8-K